N
HARP

Nuveen’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Nuveen’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,104
Closed -$231K – 3568
2022
Q1 		$231K Hold
5,104
– – ﹤0.01% 3165
2021
Q4 		$315K Buy
5,104
+177
+4% +$12.1K ﹤0.01% 3169
2021
Q3 		$431K Sell
4,927
-6,860
-58% -$690K ﹤0.01% 3194
2021
Q2 		$1.64M Buy
11,787
+2,080
+21% +$397K ﹤0.01% 2801
2021
Q1 		$2.03M Sell
9,707
-162
-2% -$32.5K ﹤0.01% 2618
2020
Q4 		$1.64M Buy
9,869
+1,408
+17% +$218K ﹤0.01% 2605
2020
Q3 		$1.44M Sell
8,461
-8,998
-52% -$1.3M ﹤0.01% 2515
2020
Q2 		$2.9M Buy
17,459
+2,836
+19% +$442K ﹤0.01% 2180
2020
Q1 		$1.69M Buy
14,623
+13,048
+828% +$1.83M ﹤0.01% 2270
2019
Q4 		$233K Hold
1,575
– – ﹤0.01% 3061
2019
Q3 		$215K Buy
+1,575
New +$221K ﹤0.01% 3112

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen's HARP Position: Q2 2022 in Review

Nuveen sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q2 2022, closing a stake of 5,104 shares — an estimated $231K sold.

Nuveen first reported a position in HARP in Q3 2019 and held it in 11 quarters. The position peaked at $2.9M in Q2 2020. 63 funds tracked by Wall St. Rank hold HARP as of Q2 2022.

  • Nuveen reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 5,104 Harpoon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $231K.
  • Nuveen first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q3 2019 and held it in 11 quarters.
  • Nuveen's Harpoon Therapeutics, Inc. Common Stock position peaked at $2.9M in Q2 2020.
  • 63 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.